A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.

We deliver transformative solutions that power real results. See how we can help.

Optimizing Supply Chain
Integrating Pharmacy
Maximizing Value-Based Care

Transforming healthcare is more than our objective, it’s in our DNA. We’re dedicated to ensuring better health is just the beginning.

At every level of leadership, Premier’s experts are driving healthcare forward.

Board of Directors
Speakers Bureau

Premier is more than a GPO. Combining robust analytics with consulting and advocacy, we’re changing the healthcare landscape for the better.  

Collective purchasing power lowers costs across your organization.

Intelligence plus unparalleled analytics equals data-driven solutions.

It’s only impossible until it’s not. Premier and our team of experts are transforming care delivery.

Work with Premier members to lower costs, improve quality and safety and succeed in value-based care.

A voice for better healthcare policy is a voice for you.  

Working closely with our members, we’re developing products and services to solve your most complex challenges.

Lower costs, greater efficiencies and a healthier bottom line.

Proven practices that result in better outcomes.

Intersecting specialty drugs with better management and data-driven best practices.

Controlling your future with integrated care delivery practices.

More savings and ROI is a win-win.

Data diving to deliver insights you can act on.

Data, inquiry and intervention services.

Our most recent insights, articles and more, all in one place.  

Discover what leading healthcare providers are achieving through Premier membership.

Stay informed with our white papers, webinars and e-books.

Browse our blog for a taste of what’s new and what’s next in healthcare.

Premier’s perspectives have been solicited by nationally renowned publications. Read on.

Read Premier’s latest announcements.

Catch our policy statements and perspectives on the latest in DC.

Biosimilars Competition Act Letter

The Honorable John Sarbanes
U.S. House of Representatives
Washington, DC 20515
The Honorable Bill Johnson
U.S. House of Representatives
Washington, DC 20515

Dear Congressman Sarbanes and Congressman Johnson:

We are writing to express our support for the Biosimilars Competition Act of 2018 (H.R. 6478). The undersigned stakeholders share your commitment to promoting a biosimilars market that will help reduce prescription drug costs for patients, payers, and taxpayers. We commend you for introducing this important legislation and look forward to working with you to enact it into law.

Spending on biologic drugs in the United States totaled more than $105 billion in 2016, and approximately two-thirds of drug spending in Medicare Part B is on biologic drugs. In 2010, the Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) with the intent of providing an approval pathway for lower-cost biosimilar products while preserving incentives for innovation. With an expected cost of 15% to 40% less than originator products, biosimilars create a significant savings opportunity across the U.S. healthcare system. Enhancing competition between biosimilar and biologic manufacturers is vital to reducing prescription drug costs for American families.

Regulators have long paid attention to settlements between brand and generic drugmakers that end patent dispute litigation to determine whether they are hindering the introduction of generics onto the market, denying patient access to lower-cost treatments. A 2003 law requires those settlements to be submitted to the Federal Trade Commission (FTC) and Department of Justice (DOJ) so antitrust regulators can challenge anticompetitive settlements in federal court. That requirement, however, does not apply to settlements between biologic and biosimilar manufacturers.

Two recent patent litigation settlements on Humira, the best-selling biologic in the United States, will not allow biosimilar versions onto the market in the United States until 2023 – five years later than in the European Union. Under current law, the FTC and DOJ have no insight into those settlements or any other potential settlements on biosimilars. The Biosimilars Competition Act of 2018 would appropriately give federal antitrust regulators the information needed to determine whether those settlements could delay the entry of lower cost biosimilars and challenge anticompetitive agreements in federal court.

We applaud your commitment to increasing patient access to lower cost, life-saving biosimilars, and we look forward to working with you to enact this important legislation into law.


Academy of Managed Care Pharmacy (AMCP)
America’s Health Insurance Plans (AHIP)
Blue Cross Blue Shield Association (BCBSA) Campaign for Sustainable Rx Pricing (CSRxP) Coalition for Affordable Prescription Drugs (CAPD) Community Catalyst
CVS Health Express Scripts Families USA Magellan Rx
National Association of Chain Drug Stores (NACDS) Pharmaceutical Care Management Association (PCMA) Premier healthcare alliance
Prime Therapeutics
Public Citizen
Public Sector HealthCare Roundtable
Teachers’ Retirement System of Kentucky

About Premier, Inc.

Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of approximately 4,000 U.S. hospitals and health systems and approximately 165,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram, and Premier’s blog for more information about the company.

Login Register Change Registration